Therapy News and Research

RSS

EC approves Sosei’s Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

1 Oct 2012

Home delivery of stroke rehabilitation improves care, eliminates waiting lists and saves costs

Home delivery of stroke rehabilitation improves care, eliminates waiting lists for treatment and saves hundreds of thousands of dollars annually in hospital costs, according to a quality improvement project presented today at the Canadian Stroke Congress.

1 Oct 2012

Administering immunotherapy for three years can reduce allergies, asthma in children

When children suffer from dust mite induced allergies and asthma, finding relief can seem impossible. While there isn't a complete cure for childhood respiratory allergies, researchers have found that long term control of allergic asthma can occur after only three years of allergy shots.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Rehabilitation robots help identify and customize post-stroke therapy

When it comes to stroke rehabilitation, it takes a dedicated team to help a person regain as much independence as possible: physicians, nurses, physiotherapists, occupational therapists, speech-language pathologists, recreation therapists, caregivers and others. Now, a University of Calgary research team has added a robot to help identify and customize post-stroke therapy.

1 Oct 2012

HR status defines two different subsets of HER2 positive cancers

Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.

1 Oct 2012

September issue of JNCCN publishes two prostate cancer articles

Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN - The Journal of the National Comprehensive Cancer Network. The articles review and clarify recent updates made to the National Comprehensive Cancer Network's (NCCN) guidelines for the screening and treatment of prostate cancer.

29 Sep 2012

Sorafenib does not improve overall survival among patients with NSCLC

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

29 Sep 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

First report to study clonal population of maxillary sinus carcinoma

Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to a study published today by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

29 Sep 2012

Drug combinations show promise against metastatic melanoma

Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

The online journal PLOS ONE released a scientific report on the validation of Falcon Genomics' Cancer BioChip System (CBCS) as a tool for identifying inhibitors of breast cancer.

29 Sep 2012

Cardiac Dimensions commences commercialization of CARILLON mitral contour system in Europe

Cardiac Dimensions, Inc. today announced that it has initiated its commercial efforts in Europe, treating the first patients with its CARILLON Mitral Contour System under its Conformite Europeenne (CE) Mark approval.

29 Sep 2012

FDA approves Boston Scientific’s S-ICD system to treat sudden cardiac arrest

The U.S. Food and Drug Administration has granted Boston Scientific Corporation regulatory approval for its S-ICD System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA).

29 Sep 2012

GCE group, Dehaier partner to distribute EASE II products in China

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has signed a two-year distribution agreement with GCE group, a leading global compressed gas-equipment company, to become the exclusive distributor for GCE's EASE II products in Mainland China.

29 Sep 2012

Therapy News and Research

EC approves Sosei’s Seebri Breezhaler to treat COPD

Home delivery of stroke rehabilitation improves care, eliminates waiting lists and saves costs

Administering immunotherapy for three years can reduce allergies, asthma in children

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Crizotinib effectively treats patients with ALK-positive lung cancer

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Rehabilitation robots help identify and customize post-stroke therapy

HR status defines two different subsets of HER2 positive cancers

September issue of JNCCN publishes two prostate cancer articles

Sorafenib does not improve overall survival among patients with NSCLC

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

First report to study clonal population of maxillary sinus carcinoma

Drug combinations show promise against metastatic melanoma

Synta announces results from ganetespib Phase 2b trial on NSCLC

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

Cardiac Dimensions commences commercialization of CARILLON mitral contour system in Europe

FDA approves Boston Scientific’s S-ICD system to treat sudden cardiac arrest

GCE group, Dehaier partner to distribute EASE II products in China

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News